Sanjay MaraboyinaSantanu SamantaSanjay Maraboyina and Santanu Samanta were named to leadership positions by the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences to support the growth of UAMS Baptist Health Cancer Centers planned across the state.
Texas A&M University Health Science Center was awarded a five-year, $6 million grant from the Cancer Prevention and Research Institute of Texas to support the creation of a Texas Regional Excellence in Cancer Center.
Scott Ness received $2.2 million in renewed funding from the National Institute of Dental and Craniofacial Research for his grant, “Mutations and Target Genes in Adenoid Cystic Carcinoma.”
The University of Chicago Medicine Comprehensive Cancer Center was added as a member institution to the National Comprehensive Cancer Network.
MetroHealth completed its vector and cellular Good Manufacturing Practice facility that will enable quick, reliable production and processing of the latest cellular immunotherapies, including CAR T-cell and tumor-infiltrating lymphocytes cancer therapies.
The Klein College of Media and Communication at Temple University announced the Margaret Foti Scholarship Fund, the first fully funded graduate level scholarship in the college’s history.
The American Society of Clinical Oncology has published updated guidelines for the initial management of noncastrate advanced, recurrent, or metastatic prostate cancer.
The number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers, according to a study published in JAMA Internal Medicine.
A phase II study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy showed that a novel monoclonal antibody, known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body.
An international group of researchers led by Children’s Hospital of Philadelphia, Winship Cancer Institute of Emory University, and the New Approaches to Neuroblastoma Therapy Consortium showed that the targeted therapy Lorbrena (lorlatinib) is safe and effective in treating high-risk neuroblastoma.
